… metastatic castration-sensitive prostate cancer (mCSPC) and … such as abiraterone acetate (Zytiga), enzalutamide (Xtandi), apalutamide … to castration-resistant prostate cancer. Recognizing this … landscape in advanced prostate cancer management. Combination …

… patient groups, including Prostate Cancer UK, reimbursement authority … ; Johnson's Zytiga brand and generics – to … treatment of hormone-sensitive prostate cancer (HSPC), having … campaigning for widespread prostate cancer screening using PSA testing …

… Castration-sensitive Prostate Cancer Market  Rising prostate cancer incidence and ageing populations Prostate cancer incidence is … for prostate cancer. The company is currently evaluating capivasertib in combination with ZYTIGA …

… Many men diagnosed with prostate cancer already have cardiovascular … ). Common treatments for prostate cancer, such as androgen … localized high-risk prostate cancer treated with preoperative … with or without abiraterone (Zytiga, Janssen). At baseline, …

… metastatic castration-sensitive prostate cancer (mCSPC). The … , including abiraterone acetate (Zytiga), enzalutamide (Xtandi), apalutamide … patients with metastatic prostate cancer often prioritize … in managing advanced prostate cancer. Medical oncologists, …

… of metastatic castration-sensitive prostate cancer, with particular attention to … apalutamide (Erleada), abiraterone acetate (Zytiga), and darolutamide (Nubeqa), were … ongoing evolution of metastatic prostate cancer management. While acknowledging that …

… management of metastatic castration-sensitive prostate cancer (mCSPC). The conversation … apalutamide (Erleada), abiraterone acetate (Zytiga), and darolutamide (Nubeqa) were … standing role in metastatic prostate cancer. Panelists emphasized its effectiveness …

… across the spectrum of advanced prostate cancer. Building on their prior … abiraterone acetate (Zytiga)—for very high-risk localized prostate cancer. Patel explains … insights for clinicians navigating complex prostate cancer cases and underscores how …

… mutated metastatic castration-sensitive prostate cancer (mCSPC). Akeega, … ’s androgen-directed prostate cancer med Zytiga (abiraterone acetate) … options across the prostate cancer continuum," the … treatment landscape for prostate cancer has advanced in …

… rapidly evolving management of metastatic prostate cancer, emphasizing practical decision-making, … patients with metastatic hormone-sensitive prostate cancer (mHSPC). Participants reaffirmed … steered toward abiraterone acetate (Zytiga) due to cost advantages …